Discovery/R&D

  1. Gene Therapies For Ocular Disease With SparingVision's Stéphane Boissel 3/28/2022

    Since assuming the President and CEO role at SparingVision in August 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company'S foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development.

  2. Reprogramming Human Cells With bit.bio's Mark Kotter, M.D. 2/12/2024

    The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.

  3. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

  4. Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed 1/23/2023

    Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery efforts, which have yielded a wide range of multi-modal candidates spanning a range of cancer indications. Our discussion digs into the company's transition from R&D to the clinic, how its built an uncommonly comfortable cash position through partnership, and its ambition to become a fully-integrated commercial-stage biotech.

  5. Building A Biotech Around Your Therapeutic Platform 8/13/2020

    Heat Biologics founder and CEO Jeff Wolf took a creative approach to building his company. With the science behind his company's platform to activate immune responses against pathogenic or cancer antigens in place, he proceeded to structure the organization and its people in a strategic fashion to support that platform. Learn how he did it–and how Heat's management philosophy is driving innovation and efficiency there–on this episode of The Business Of Biotech: Summer Executive Sessions.

  6. Antibody Cocktails With Immunome's Dr. Purnanand Sarma 7/6/2022

    Immunome CEO Purnanand Sarma, Ph.D. joins the Business of Biotech for a discussion on precision antibodies and his company's discovery platform, which identifies novel therapeutic antibodies and their antigen targets by leveraging highly educated memory B cells from patients who have learned to fight off their disease. It’s kind of like picking an all-star team of players who have been in the game, and who are well-trained to win. On today's episode we'll learn how they’re discovered, how they’re developed, and how they’re applied in cancer and coronavirus.

  7. Therapeutic Molecules From Moss with eleva's Andreas Schaaf And Björn Cochlovius, Ph.D. 4/20/2023

    We kick this conversation off with the writer Elizabeth Gilbert's take on moss, which she so eloquently dubs a "resurrection engine." Gilbert almost certainly didn't realize the potential of moss to play a resurrectional role in human health, but Eleva Biotech's Andreas Schaaf and Björn Cochlovius do. On this episode of the Business of Biotech, we learn about a company that's developing proteins to fuel its own pipeline — and its partners' — from a most ubiquitous plant that grows virtually everywhere. It grows particularly well in bioreactors outfitted with custom grow lights and presents some significant advantages over CHO cell line development.

  8. Digital Transformation In Cell Therapy with Organicell Drs. Mari Mitrani & Michael Bellio 5/3/2021

    Drs. Mari Mitrani, CSO and Michael Bellio, Laboratory Director are young pioneers in the study of the therapeutic potential of exosomes. Their research leans heavily into the digital realm, leveraging computational biology, bioinformatics, large-scale sequencing, proteomics, and mass spectrometry to analyze perinatal tissue-secreted exosomes and their impact on a host of indications the company is exploring. On this episode of The Business Of Biotech, Drs. Mitrani and Bellio offer insight into the digital discovery and manufacturing automation technologies in use at Organicell.

  9. Myeloid Cells, Transplants, & Immuno-Oncology Inspiration 8/16/2020

    OSE Immunotherapeutics CEO Alexis Peyroles joins The Business Of Biotech: Summer Executive Sessions to discuss myeloid cells' role in immunology, why a team of transplant specialists is key to his company's therapeutic development approach, and creating differentiation as a clinical-stage immunotherapy company in an ever-growing sea of competitors. 

  10. Med Device Meets Biopharma With OncoSec's Dan O'Connor, J.D. 5/17/2021

    OncoSec CEO & Director Dan O'Connor, J.D. joins the Business of Biotech to discuss his company's development of proprietary application and injection technologies for direct delivery of its pipeline of immunotherapeutic candidates and combination therapies into the tumor environment. O'Connor shares leadership lessons gleaned from his service as a Captain in the United States Marine Corps during Operation Desert Shield, and how he's applied those lessons as his company charts the manufacturing and regulatory challenges along its unique development timeline.